Benzinga | Dec 15, 2020 11:11AM EST

Morgan Stanley Maintains Underweight on Abiomed, Raises Price Target to $238

Morgan Stanley maintains Abiomed (NASDAQ:ABMD) with a Underweight and raises the price target from $217 to $238.